Shire buys U.S.-based Foresight Biotherapeutics Inc for $300 million

(Reuters) - Pharmaceuticals company Shire Plcsaid it had bought New York-based Foresight Biotherapeutics Inc for $300 million, gaining access to a late-stage therapy being developed for the...